Medical school

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
火曜日, 4月 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.

Cytonus Therapeutics Expands C-suite as it Transitions to a Clinical Stage Company

Retrieved on: 
月曜日, 4月 22, 2024
Health, Infectious Diseases, Health Technology, General Health, Pharmaceutical, Biotechnology, Doctor of Philosophy, Administration, University, LEGO, Information, Master of Business Administration, M.B.A, Intellectual property, Commercialization, Partnering, McKinsey & Company, Business administration, Corporate development, Duke University, Senior, Patent, Bachelor of Arts, Virginia Tech, Medical school, Physician, Therapy, Management

Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.

Key Points: 
  • Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.
  • In addition, Cytonus has added Sherry M. Carty, Ph.D., as Director of Intellectual Property and Karen Markham has been promoted to Chief Administrative Officer.
  • Prior to Inova, he was a member of MedImmune/AstraZeneca's Partnering & Strategy Leadership Team, a healthcare venture capitalist and a strategy consultant with McKinsey and Company.
  • Mrs. Markham has been promoted to Chief Administrative Officer at Cytonus, where she oversees all administrative functions.

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Retrieved on: 
木曜日, 4月 18, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical school, University, Cancer, The Lancet, Journal of Clinical Oncology, Lung cancer, Clinical Cancer Research, NDA, Pancreatic cancer, Hematology, Internal medicine, RAS, Nektar, Leukemia, Patient, Data management, Northeast Ohio Medical University, Blood, Nektar Therapeutics, Therapy, Journal, Verastem Oncology

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.
  • “John is a recognized leader in oncology with broad expertise across cancer research and development, business development and organizational leadership, and we welcome him to the Verastem team,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
  • Dr. Hayslip received his medical degree from Northeast Ohio Medical University and a master’s degree in clinical research from the Medical University of South Carolina.
  • Following his residency in internal medicine, Dr. Hayslip completed his fellowship in hematology-oncology at the Medical University of South Carolina, leading to dual board certifications in both hematology and medical oncology.

Dermatology and Laser Center of Charleston Joins Epiphany Dermatology

Retrieved on: 
月曜日, 4月 22, 2024
Alternative Medicine, Surgery, General Health, Health, Consumer, Cosmetics, Other Consumer, Other Health, Medical school, Biomedical sciences, State university system, Partnership, Skin care, Entrepreneurship, Patient, Cleveland Clinic, Marketing, SUNY

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.

Key Points: 
  • Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.
  • Founded in 2005 by Dr. Schlesinger, Dermatology and Laser Center of Charleston has a solid reputation of providing high-quality dermatology and cosmetic services to patients in Charleston, SC, and surrounding communities.
  • I look forward to helping Epiphany maintain its high standards of quality patient care.”
    Gheorghe Pusta, Co-Founder and Chief Executive Officer of Epiphany said, “We are excited to welcome Dr. Schlesinger and his team to Epiphany.
  • Epiphany also benefits from the clinical expertise of Dermatology and Laser Center of Charleston’s team, as best practices are collaboratively shared across the Epiphany network.

Rural Higher Ed Institutions Team Up to Boost Community Resilience and Economic Mobility for Rural Learners

Retrieved on: 
火曜日, 4月 23, 2024
Education, Medical school, Spokane Community College, University, Lab, Institute of technology, Partnership, Employment, Work, Orangeburg–Calhoun Technical College, Tutoring

WASHINGTON, April 23, 2024 /PRNewswire/ -- The Education Design Lab (the Lab) today announced the launch of its new Rural College Design and Data Academy. This academy comprises institutions based in rural areas throughout the nation that will work together to strengthen the capacity of rural colleges to design and implement new pathways to economic mobility for rural learners – and measure their success. Underpinned by the learnings from the Lab's Building Rural Innovation, Designing Educational Strategies (BRIDGES) Design Challenge, participating institutions will evaluate their program's impact on learners' education, employment, and economic outcomes using the Lab's Data Collaborative for a Skills-Based Economy (Data Collab) infrastructure.

Key Points: 
  • Education Design Lab will convene rural-serving higher education institutions to develop skill-based programs aimed at creating new opportunities for rural learners and communities.
  • This academy comprises institutions based in rural areas throughout the nation that will work together to strengthen the capacity of rural colleges to design and implement new pathways to economic mobility for rural learners – and measure their success.
  • "The innovative models championed by the Lab encourage rural learners to pursue higher education options and pave the way for sustainable economic growth for rural communities."
  • Since its founding in 2013, the Education Design Lab has worked to strengthen the capacity of higher education institutions and community colleges which serve "New Majority Learners," or learners from previously "nontraditional" backgrounds including learners of color, learners from low-income backgrounds, and rural learners.

Kaiser Permanente Bernard J. Tyson School of Medicine appoints Dr. John L. Dalrymple as new Dean and CEO

Retrieved on: 
火曜日, 4月 16, 2024
Education, Harvard University, University, Reproductive biology, Moses Austin, Medical school, Hospital, Teaching, School, Health, Doctor of Philosophy, Brigham, Dell Medical School, MD Anderson Cancer Center, History, Medical education, OBGYN, Curriculum, Cone Health Women's Hospital, Dalrymple, Medicine, Ellen, Faculty, Harvard Medical School, Student, Massachusetts General Hospital, Nursing

PASADENA, Calif., April 16, 2024 /PRNewswire/ -- Today, the Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) announced the appointment of physician, educator, and women's health expert John L. Dalrymple, MD, as the school's new Dean and CEO after an extensive national search. Dr. Dalrymple brings a wealth of academic leadership and teaching experience, respected expertise as a practicing physician, a proven record of delivering quality medical education and a commitment to advancing equitable healthcare. Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.

Key Points: 
  • Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.
  • Dr. Dalrymple currently serves as the senior associate dean for Medical Education at Harvard Medical School.
  • Together, we will ensure that our school remains at the forefront of innovation, equity, compassionate care, and excellence in medical education."
  • "I am deeply honored and immensely humbled to become part of this innovative, vibrant, and forward-thinking school and world-class healthcare organization.

SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series

Retrieved on: 
金曜日, 4月 12, 2024
Medical school, Immunotherapy, Society, Bangladesh Technical Education Board, Chairperson, AI, DRSN, Series, MD, Doctor of Philosophy, National Cancer Institute, Research, Artificial intelligence, Intelligence, Computation, Science, NCI, SITC, Big data, IO, UPMC Hillman Cancer Center, Knowledge, Chair

MILWAUKEE, April 12, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce their collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, on the fourth Computational Immuno-oncology Webinar Series. This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

Key Points: 
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Retrieved on: 
木曜日, 4月 11, 2024
Breast cancer, VUS, Medical school, Patient, Oncogenomics, Laboratory, OTC, FACMG, Machine learning, Research, Health, REA, Genetic testing, Black, DSM-IV codes, Classification, Society, Cancer, Algorithm, SAN, Gene

SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

Key Points: 
  • The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.
  • After validating gene-specific machine learning algorithms, the impact on variant classification was analyzed in patients with breast cancer who underwent hereditary cancer genetic testing from January 2022 - May 2023.
  • Results offer reassurance that variants of uncertain significance in genetic testing results among breast cancer patients do not lead to overuse of breast surgeries, like mastectomies.
  • This study titled, "Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance," examines breast surgery uptake in a large, recent sample of breast cancer patients undergoing genetic testing.

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
水曜日, 4月 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
水曜日, 4月 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .